Trials / Completed
CompletedNCT00740207
Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA
A Phase IV Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare ISOVUE-250 and VISIPAQUE 270 for motion artifact and pain following intraarterial injection for peripheral DSA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VISIPAQUE 270 | VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution |
| DRUG | Isovue 250 | ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-08-22
- Last updated
- 2011-05-09
- Results posted
- 2011-04-18
Source: ClinicalTrials.gov record NCT00740207. Inclusion in this directory is not an endorsement.